CPEX Pharmaceuticals to discuss the clinical aspects of nasal insulin therapy

Sep 15 2009

CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) (“CPEX”) today announced that it will participate in the Ninth Annual Diabetes Technology Meeting to be held November 5–7, 2009, at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to present an oral presentation titled “The Technology and Clinical Aspects of Nasal Insulin Therapy” at 9:30 a.m. PST on Saturday, November 7, 2009.

In addition, CPEX recently completed its data analyses on four Phase 1 studies which have been accepted for poster presentations at the meeting. The posters, “A Randomized 6-Way Crossover Study of Nasulin^TM, Saline and Lispro in Subjects with Type 2 Diabetes to Determine Optimum Dose Timing”, “Two Randomized Crossover Glucose Clamp Studies of Nasulin^TM and Lispro”, “Dose-Exposure for Single and Dual Nostril Administration of Nasal Insulin (Nasulin^TM)” and “Dose-Exposure for Two Dose Strengths of Nasal Insulin (Nasulin^TM)” will be displayed during the Poster Presentation Sessions of the meeting on Thursday and Friday, November 5 and 6, 2009.

http://www.cpexpharm.com/